ClinVar Miner

Submissions for variant NM_000303.3(PMM2):c.470T>C (p.Phe157Ser)

gnomAD frequency: 0.00054  dbSNP: rs190521996
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 17
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Illumina Laboratory Services,Illumina RCV000169083 SCV000399675 pathogenic PMM2-congenital disorder of glycosylation 2017-04-27 criteria provided, single submitter clinical testing Across a selection of the available literature, the PMM2 c.470T>C (p.Phe157Ser) missense variant is reported in a compound heterozygous state with a second variant in eight patients with congenital disorder of glycosylation type 1a (CDG1a), and in one patient where zygosity information is not provided (Matthijs et al. 1999; Briones et al. 2002; Noelle et al. 2005; Romano et al. 2009; Vega et al. 2011; Casado et al. 2012; Resende et al. 2014). Nearly all of these patients exhibited a severe phenotype and residual PMM2 enzyme activity in patient fibroblasts was extremely low or undetectable. Control data are unavailable for this variant, which is reported at a frequency of 0.00081 in the European American population of the Exome Sequencing Project. Analysis of the p.Phe157Ser variant in a prokaryotic expression system showed that the variant affected the stability and structure, and significantly decreased the half-life of the protein (Vega et al. 2011). Based on the collective evidence, the p.Phe157Ser variant is classified as pathogenic for congenital disorders of glycosylation. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population.
GeneDx RCV000481553 SCV000568193 pathogenic not provided 2022-08-15 criteria provided, single submitter clinical testing Published functional studies demonstrate this variant results in complete loss of enzyme activity and may impact the stability and/or structure of the protein (Romano et al., 2009; Vega et al., 2011); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 17166182, 15844218, 15645285, 29482223, 11343337, 18948042, 19396570, 22012410, 19357119, 10527672, 11156536, 24739649, 28373276, 17920054, 12705494, 12607543, 23430838, 17158594, 25497157, 25355454, 21541725, 32304219, 32630370, 33580824, 32841164, 33643843, 33413482, 31589614, 34598035)
Victorian Clinical Genetics Services,Murdoch Childrens Research Institute RCV000169083 SCV000680022 pathogenic PMM2-congenital disorder of glycosylation 2022-06-24 criteria provided, single submitter clinical testing Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with congenital disorder of glycosylation, type Ia (MIM#212065). (I) 0106 - This gene is associated with autosomal recessive disease. (I) 0115 - Variants in this gene are known to have variable expressivity. The clinical manifestations and course are highly variable, ranging from infants who die in the first year of life to mildly affected adults. (GeneReviews). (I) 0200 - Variant is predicted to result in a missense amino acid change from phenylalanine to serine. (I) 0251 - This variant is heterozygous. (I) 0304 - Variant is present in gnomAD <0.01 for a recessive condition (v2: 91 heterozygotes, 0 homozygotes). (SP) 0501 - Missense variant consistently predicted to be damaging by multiple in silico tools or highly conserved with a major amino acid change. (SP) 0604 - Variant is not located in an established domain, motif, hotspot or informative constraint region. (I) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals. It has been reported in at least twenty individuals with congenital disorder of glycosylation, including compound heterozygotes (PMID: 33340551). (SP) 1205 - This variant has been shown to be maternally inherited (by trio analysis). (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000169083 SCV000696500 pathogenic PMM2-congenital disorder of glycosylation 2016-06-03 criteria provided, single submitter clinical testing Variant summary: The PMM2 c.470T>C (p.Phe157Ser) variant causes a missense mutation involving a conserved nucleotide with 5/5 in silico tools predicting a damaging outcome, which functional studies support this prediction. The variant of interest was observed in the large, broad control population, ExAC, with an allele frequency of 33/121274 (1/3675), which does not exceed the estimated maximal expected allele frequency for a pathogenic PMM2 variant of 1/178. (0.0055902). The variant of interest has been reported in multiple affected individuals via publications, along with a reputable clinical laboratory citing the variant as "likely pathogenic." Therefore, taking all available lines of evidence into consideration, the variant of interest has been classified as Pathogenic.
Invitae RCV000169083 SCV000757672 pathogenic PMM2-congenital disorder of glycosylation 2021-11-24 criteria provided, single submitter clinical testing This sequence change replaces phenylalanine, which is neutral and non-polar, with serine, which is neutral and polar, at codon 157 of the PMM2 protein (p.Phe157Ser). This variant is present in population databases (rs190521996, gnomAD 0.06%). This missense change has been observed in individual(s) with congenital disorder of glycosylation type Ia (PMID: 11156536, 15645285, 19357119, 21541725, 22012410, 24739649, 25355454). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 188763). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt PMM2 protein function. Experimental studies have shown that this missense change affects PMM2 function (PMID: 21541725). For these reasons, this variant has been classified as Pathogenic.
Fulgent Genetics,Fulgent Genetics RCV000169083 SCV000894092 likely pathogenic PMM2-congenital disorder of glycosylation 2018-10-31 criteria provided, single submitter clinical testing
Baylor Genetics RCV000169083 SCV001163404 pathogenic PMM2-congenital disorder of glycosylation criteria provided, single submitter clinical testing
Myriad Women's Health, Inc. RCV000169083 SCV001194005 pathogenic PMM2-congenital disorder of glycosylation 2019-12-20 criteria provided, single submitter clinical testing NM_000303.2(PMM2):c.470T>C(F157S) is classified as pathogenic in the context of congenital disorder of glycosylation type Ia. Sources cited for classification include the following: PMID 11156536, 17166182, 12607543, 12705494, 19396570, 17920054, 21541725 and 15645285. Classification of NM_000303.2(PMM2):c.470T>C(F157S) is based on the following criteria: This is a well-established pathogenic variant in the literature that has been observed more frequently in patients with clinical diagnoses than in healthy populations. Please note: this variant was assessed in the context of healthy population screening.
Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen RCV000481553 SCV001905595 pathogenic not provided 2021-09-15 criteria provided, single submitter clinical testing
Genetic Services Laboratory,University of Chicago RCV000481553 SCV002064318 likely pathogenic not provided 2021-11-15 criteria provided, single submitter clinical testing DNA sequence analysis of the PMM2 gene demonstrated a sequence change, c.470T>C, in exon 6 that results in an amino acid change, p.Phe157Ser. This sequence change has been described in the gnomAD database with a frequency of 0.06% in the non-Finnish European subpopulation (dbSNP rs190521996). This sequence change has been described in the compound heterozygous state with other pathogenic/likely pathogenic variants in individuals with PMM2-related disorder (PMIDs: 24739649, 15645285, 11156536, 19357119, 25355454, 22012410). The p.Phe157Ser change affects a highly conserved amino acid residue located in the cap domain of the PMM2 protein. The p.Phe157Ser substitution appears to be deleterious using several in-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL). Functional studies suggest p.Phe157Ser disrupts the stability and activity of the PMM2 protein (PMID: 21541725). Collectively, this evidence suggests p.Phe157Ser is likely pathogenic.
Mayo Clinic Laboratories,Mayo Clinic RCV000481553 SCV002520057 pathogenic not provided 2021-05-13 criteria provided, single submitter clinical testing PS3, PS4, PM2, PM3_strong, PP3, PP4
Laboratorio de Genetica e Diagnostico Molecular, Hospital Israelita Albert Einstein RCV002252013 SCV002522794 pathogenic See cases 2021-01-29 criteria provided, single submitter clinical testing ACMG classification criteria: PS3, PS4, PM3
Natera, Inc. RCV000169083 SCV001457176 pathogenic PMM2-congenital disorder of glycosylation 2020-09-16 no assertion criteria provided clinical testing
Genome Diagnostics Laboratory, Amsterdam University Medical Center RCV000481553 SCV001808718 pathogenic not provided no assertion criteria provided clinical testing
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ RCV000481553 SCV001951644 pathogenic not provided no assertion criteria provided clinical testing
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center RCV000481553 SCV001966443 pathogenic not provided no assertion criteria provided clinical testing
PerkinElmer Genomics RCV000169083 SCV002018867 pathogenic PMM2-congenital disorder of glycosylation 2019-06-12 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.